Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

Pfizer and BioNTech have been among the leaders in the race to bring a combined COVID-19 and influenza vaccine to market, but have stumbled in the final straight. The companies reported mixed ...

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech, which may offer quicker production and greater efficacy than ...

Also Read: DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions In October, the FDA issued the ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

This is akin to a strain change for a seasonal influenza vaccine. For the Pfizer/BioNTech and Moderna vaccines, this means ...

Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine ...

The options include the mRNA vaccines from Pfizer/BioNTech and Moderna — the vaccines that the ... just as they don’t require ...

Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval could arrive in 2025 (covid/influenza combination vaccine partnered with Pfizer), which would help put the ...

Seasonal influenza and COVID-19 vaccination uptake for risk groups such as the elderly were sub-optimal in several EU/EEA ...

This is akin to a strain change for a seasonal influenza vaccine. For the Pfizer/BioNTech and Moderna vaccines, this means that small changes were made to the mRNA in the vaccine so that the ...